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Introduction: About 70% of well-differentiated endocrine tumors arise from the gastrointestinal tract. Duodenal
well-differentiated endocrine tumors account for only 2.6% of all neuroendocrine tumors. Following the first two
case reports of somatostatin-secreting tumors in 1977, fewer than 200 cases of somatostatinoma have been
reported. These tumors of the duodenum are usually silent and asymptomatic, but can cause gastrointestinal
symptoms. Depending on the localization of the tumor, multiple surgical procedures can be performed, ranging
from local resection to pancreaticoduodenectomy.
Case presentation: Here, we report a case of a submucosal duodenal mass in a 42-year-old Turkish White man
presenting with nausea, vomiting, fatigue and abdominal pain. The treatment decision of
pancreaticoduodenectomy made preoperatively was later altered to intraoperative removal via local resection with
sphincteroplasty.
Conclusion: Tumors of the periampullary region are considered highly malignant, and the Whipple operation is
usually the only procedural treatment. In the current case, we decided not to perform pancreaticoduodenectomy
but to excise the mass intraoperatively, and consequently avoided unnecessary resection of the pancreas and
anastomosis to undilated hepatic and pancreatic ducts. This protective strategy prevented duodenum- and
pancreas-related morbidity.
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Carcinoid tumors of the duodenum are usually hormo-
nally silent endocrine cell tumors. Langhans is often
credited with the first description of a gut carcinoid tumor
in 1867 [1]. Gastroenteropancreatic endocrine tumors are
rare neoplasms, with one to four cases documented per
100,000 people each year [2]. Since the first two case
reports of somatostatin-secreting tumors in 1977, fewer
than 200 cases of somatostatinoma have been reported
[3]. Classification of neuroendocrine tumors (NETs) of the
duodenum is based on hormone production, for instance,
carcinoid (serotonin), somatostatinoma, or gastrinoma,
because each induces a distinct clinical syndrome. About
70% of well-differentiated endocrine tumors (WDET)
arise from the gastrointestinal tract [4]. Duodenal WDETs
account for only 2.6% of all NETs [5,6]. Ileal NETs and/or* Correspondence: oguzcoach@yahoo.com
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reproduction in any medium, provided the orcarcinoids are frequently located in the small bowel
(>70%), but recent studies have shown that NETs of the
duodenum are more commonly encountered (22%) [7].
Somatostatin-producing tumors also give rise to the som-
atostatin syndrome, which was initially reported by Krejs
et al. in 1979 [8]. Typical somatostatin syndrome com-
prises the triad of diabetes mellitus, cholelithiasis, and
steatorrhea [8]. These tumors can be excised using inva-
sive or noninvasive procedures, depending on their
localization.
In our case, because histopathologic findings were
insufficient and unconfirmed preoperatively, a pancreati-
coduodenectomy was planned, but after intraoperative
exploration, the mass was thought to be a NET and
resected locally, with frozen section examination showing
malignancy-free margins. Neuroendocrine cell tumors
should always be considered if found in the periampullary
region, as in our case. Here, we have reported a case of
nonfunctional duodenal somatostatinoma showing re-
gional lymph node and sphincter of Oddi metastases, and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Image of the pathological examination with paraffin
embedding and staining.
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comes of this disease.
Case presentation
The patient was a 42-year-old Turkish White man present-
ing with nausea, vomiting, fatigue and abdominal pain. La-
boratory data revealed no abnormalities in blood chemistry
or tumor markers. An enzyme-linked immunosorbent
assay disclosed positivity for HBsAg. No abnormal findings
were observed in the chest X-ray. Computed tomography
revealed thickening at the second and third portions of the
duodenal wall and a polypoid contrast-enhanced area. Be-
cause a gastroduodenoscopy showed no abnormalities, an
endoscopic retrograde cholangiopancreatography (ERCP)
was performed. The ERCP revealed a duodenal mass.
Biopsy specimens derived by ERCP were highly suspi-
cious for malignancy. Subsequent color Doppler exam-
ination performed for abdominal aorta and portal vein
invasion did not reveal any abnormalities. The plan was
to perform a pancreaticoduodenectomy, and 10 days
later the patient underwent surgery. A mobile, polyp-
oid, palpable tumor was further uncovered in the third
portion of the duodenum, distal to the duodenal pa-
pilla. Pancreas, papilla and duodenal wall except the
third portion seemed to be free from the polypoid
mass. Considering the possibility of a NET tumor, the
relatively invasive procedure was postponed, complete
tumoral tissue was excised locally, and the specimen
sent for frozen section examination. Pathological exam-
ination revealed that resected tumor margins were free
of malignancy. However, owing to the proximity of the
tumor to the ampulla of Vater, a sphincteroplasty was
conducted to prevent potential obstruction. In addition,
cholecystectomy and choledochotomy procedures were
performed, and a T-tube inserted into the choledochus.
Finally, all the enlarged lymph nodes were resected.
Pathological examination with paraffin embedding and
staining disclosed a 1.7cm well-differentiated, Grade 1
neuroendocrine carcinoma (NEC) (Figure 1). Tumor
cells were detected in the muscularis propria of the
sphincter of Oddi. Lymphovascular invasion of tumor
cells (a total of eight lymph nodes) was positive.
According to the TNM staging system, the tumor was
classified as pT2. The tumor consisted of uniform cells
formed in glandular patterns. Tumor cells were stained
for chromogranin A, synaptophysin and somatostatin.
The final diagnosis was made by the pathology unit as
primary duodenal somatostatinoma. The proliferation
index was high and because of the lymphovascular inva-
sion, the tumor was thought to be malignant. Because the
patient had been operated on for papillary thyroid cancer
6 years earlier, the possibility of multiple endocrine neo-
plasia was excluded. The level of neuron-specific enolase
was 14.4ng/mL at the second postoperative week. Thepatient was discharged from the hospital with no compli-
cations on postoperative day 22.
Discussion
Carcinoid tumors of the duodenum are generally low-
grade NETs. The term ‘neuroendocrine’ is derived based
on similarities between these cells and neural cells in
terms of expression of specific proteins, such as
synaptophysin, neuron-specific enolase and chromogranin
A [9]. These tumors arise from enterochromaffin cells of
the gastrointestinal tract. The gastrointestinal tract con-
tains at least 14 different endocrine cell types, including
enterochromaffin cells that are classically associated with
carcinoid tumors [10]. In the duodenum, most NETs are
nonfunctional, sporadic, well differentiated and slow
growing [11]. Ultimately, 22% of all NETs of the small
bowel arise from the duodenum [7]. Duodenal carcinoids
are most common in the proximal duodenum and present
as early enhancing intraluminal polyps or mural masses
[12]. The symptoms usually consist of abdominal com-
plaints, such as pain, nausea, vomiting and bleeding. The
majority of patients do not display distant organ metasta-
ses. For duodenal somatostatinomas, the somatostatin
syndrome can occur only if the tumor is larger than 4cm
[13]. Somatostatin is a cyclic tetradecapeptide secreted by
the hypothalamus, cerebrum, spinal cord, vagus nerve,
and D cells in Langerhans islets of the pancreas, stomach,
duodenum, and small intestine.
In our patient, the tumor originated from the third
portion of the duodenum and was measured as 1.7cm.
The patient presented with nonspecific gastrointestinal
symptoms, such as abdominal pain, fatigue, nausea and
vomiting. The serum insulin, glucagon, gastrin, somato-
statin and urine 5-hydroxyindoleacetic acid levels were
not assessed because the mass was not considered a
NET preoperatively. Histopathologically, a characteristic
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fied in 68% of duodenal somatostatinomas [14]. On
silver staining, the majority of carcinoid tumors are ar-
gyrophilic, but seldom argentaffinic [15]. The tumor
characteristics of our patient were consistent with those
of somatostatinoma. Gastrointestinal NETs appear at all
ages, with the highest incidence recorded from the fifth
decade upwards [16]. NETs of the stomach, duodenum,
appendix or rectum are small (≤1cm) and well differenti-
ated; they are considered ‘early’ tumors because they
generally have very good prognosis [17]. In the new
World Health Organization classification of 2010, these
neoplasms are grouped as grade 1 or 2 NETs and/or
carcinoids (NETs), and distinguished from poorly differ-
entiated NECs, G3. Duodenal carcinoids are usually
detected at the early and treatable stages as a result of
considerable progress in the latest imaging techniques.
Using these techniques, even very small lesions can be
diagnosed. The general widespread use of gastrointes-
tinal endoscopy has led to a shift in the discovery of
smaller (≤10 to 20mm) gastrointestinal NETs and/or
carcinoids at the time of diagnosis [17]. Endoscopic
ultrasound examination is highly sensitive for detecting
NETs of the duodenum because it facilitates the identifi-
cation of submucosal lesions and staging [18].
Primary surgical resection of the tumor and regional
lymph nodes is the only curative treatment for gastro-
intestinal NETs. This is usually possible in about 20% of
patients [18]. There is a wide consensus that surgery
should be recommended for tumors larger than 20mm.
Unfortunately, opinion on the optimal extent of surgical
treatment is divided, and therapeutic options for NETs
of the duodenum that are nonfunctional, well differenti-
ated and 10 to 20mm in size are controversial. The im-
pact of regional lymph node metastases on survival is
uncertain at present. Regardless of the primary tumor
size, if abnormal lymph nodes are detected, the tumor
and all the regional lymph nodes should be removed.
Burke et al. [19] identified three pathologic features of
the primary tumor as independent risk factors for me-
tastasis: invasion of the muscularis propria, size greater
than 2cm, and the presence of mitotic figures. Soga [20]
showed that lymph node metastasis is associated with
9.8% of gastrointestinal NETs with submucosal invasion,
even in cases when the tumor diameter is 1.0cm or less,
suggesting that the risk of metastasis does not differ ap-
preciably from that of carcinoma. In terms of duodenal
carcinoids, even small lesions are associated with a risk
of lymph node metastasis, which is related to tumor
diameter and depth of invasion. In general, carcinoid tu-
mors arising from the small intestine have the greatest
propensity to metastasize, even at small sizes, compared
with those in the appendix, colon and rectum [21].
Adjuvant chemotherapy for somatostatinomas is notrecommended owing to insufficient data, and palliative
chemotherapy for unresectable or advanced tumors has
limited benefits.
NETs of the small bowel are increasing in incidence.
With access to new diagnostic and imaging techniques,
detection of these tumors in the United States of America
has increased by 300% to 500% in the past 35 years. Sim-
ultaneously, prognosis of these tumors has improved con-
siderably [17]. Data from the United States of America
have revealed that the incidence of gastrointestinal NETs
has increased at a rate of 3% to 10% per year over the past
three decades [6,22]. The overall 5-year survival rate for
patients with gastrointestinal NETs and/or carcinoids has
improved by almost 20% in the last 35 years [6]. The over-
all 5-year survival rate for patients with somatostatinoma
is 40% to 60% [1], 40% in somatostatinomas with liver me-
tastasis, and 100% in tumors without liver or lymph node
metastases [23].
Tumors of the periampullary region are considered
highly malignant, and the Whipple operation is usually
the only procedural treatment. This procedure is a
pancreaticoduodenectomy, which is fairly invasive with a
number of postoperative potential complications, such
as pancreatic fistula, gastroparesis, and malabsorption.
Overall survival after Whipple operation for pancreatic
adenocarcinoma is about 20% at 5 years after surgery.
However, the optimal resection extent of duodenal
tumors has not been defined as yet. A number of re-
searchers advocate pancreaticoduodenectomy [24] for all
patients with malignant tumors of the duodenum,
including those located in the third and fourth portions,
to ensure adequate en bloc resection. If the tumor is an
adenocarcinoma or carcinoid, en bloc resection and
systemic lymph node dissection are indicated [25].
Others support pancreaticoduodenectomy for proximal
duodenal carcinoma, but segmental resection for tumors
in the third and fourth portions [26-28]. In the current
case, we decided not to perform pancreaticoduodenectomy
but to excise the mass intraoperatively, and consequently
avoided unnecessary resection of the pancreas and anasto-
mosis to undilated hepatic and pancreatic ducts. This
protective strategy prevented duodenum- and pancreas-
related morbidity.
Conclusions
Tumors of the periampullary region are considered highly
malignant, and the Whipple operation is usually the only
procedural treatment. In the current case, we decided not
to perform pancreaticoduodenectomy but instead to ex-
cise the mass intraoperatively, and consequently avoided
unnecessary resection of the pancreas and anastomosis to
undilated hepatic and pancreatic ducts. This protective
strategy prevented duodenum- and pancreas-related
morbidity.
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